There are several implications of the surge in the incidence of pandemics and epidemics in the last decades. COVID-19 being the most remarkable one, showed the vulnerability of patients with neurodegenerative diseases like Alzheimer’s disease (AD). This review studies the pathological interlinks and triggering factors between the two illnesses and proposes a multifactorial pathway of AD causation due to COVID-19. The article evaluates and describes all the postulated hypotheses which explain the etiology and possible pathogenesis of the disease in four domains: Inflammation & Neurobiochemical interactions, Oxidative Stress, Genetic Factors, and Social Isolation. We believe that a probable hypothesis of an underlying cause of AD after COVID-19 infection could be the interplay of all these factors.
TsapanouA, PapatriantafyllouJD, YiannopoulouK, SaliD, KalligerouF, NtanasiE, ZoiP, MargiotiE, KamtsadeliV, HatzopoulouM (2021) The impact of COVID-19 pandemic on people with mild cognitive impairment/dementia and on their caregivers. Int J Geriatr Psychiatry36, 583–587.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 329–344.
5.
HenekaMT, GolenbockD, LatzE, MorganD, BrownR (2020) Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther12, 1–3.
6.
ZhouF, YuT, DuR, FanG, LiuY, LiuZ, XiangJ, WangY, SongB, GuX (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet395, 1054–1062.
7.
XiaX, WangY, ZhengJ (2021) COVID-19 and Alzheimer’s disease: How one crisis worsens the other. Transl Neurodegener10, 15–32.
8.
YanR, ZhangY, LiY, XiaL, GuoY, ZhouQ (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science367, 1444–1448.
9.
JacksonCB, FarzanM, ChenB, ChoeH (2022) Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol23, 3–20.
10.
WangY, WangY, LuoW, HuangL, XiaoJ, LiF, QinS, SongX, WuY, ZengQ (2020) A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells. Int J Med Sci17, 1522–1531.
11.
LiM, LiL, ZhangY, WangX (2020) Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Povert9, 23–29.
12.
HernándezVS, ZetterMA, GuerraEC, Hernández-AraizaI, KaruzinN, Hernández-PérezOR, EidenLE, ZhangL (2021) ACE2 expression in rat brain: Implications for COVID-19 associated neurological manifestations. Exp Neurol345, 113837–113852.
13.
ZenaroE, PiacentinoG, ConstantinG (2017) The blood-brain barrier in Alzheimer’s disease. Neurobiol Dis107, 41–56.
LimaM, SiokasV, AloizouA, LiampasI, MentisAA, TsourisZ, PapadimitriouA, MitsiasPD, TsatsakisA, BogdanosDP (2020) Unraveling the possible routes of SARS-COV-2 invasion into the central nervous system. Curr Treat Options Neurol22, 1–15.
16.
BrycheB, FrétaudM, Saint-Albin DeliotA, GallouxM, SedanoL, LangevinC, DescampsD, Rameix-WeltiM, EléouëtJ, Le GofficR (2020) Respiratory syncytial virus tropism for olfactory sensory neurons in mice. J Neurochem155, 137–153.
17.
SungnakW, HuangN, BécavinC, BergM, QueenR, LitvinukovaM, Talavera-LópezC, MaatzH, ReichartD, SampaziotisF (2020) SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med26, 681–687.
18.
KlingensteinM, KlingensteinS, NeckelPH, MackAF, WagnerAP, KlegerA, LiebauS, MilazzoA (2021) Evidence of SARS-CoV2 entry protein ACE2 in the human nose and olfactory bulb. Cells Tissues Organs209, 155–164.
19.
ChenR, WangK, YuJ, HowardD, FrenchL, ChenZ, WenC, XuZ (2021) The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front Neurol11, 573095.
20.
LimK, YangS, KimS, JooJ (2020) Elevation of ACE2 as a SARS-CoV-2 entry receptor gene expression in Alzheimer’s disease. J Infect81, e33–e34.
21.
StrubleRG, DhanrajDN, MeiY, WilsonM, WangR, RamkumarV (1998)
β-Amyloid precursor protein-like immunoreactivity is upregulated during olfactory nerve regeneration in adult rats. Brain Res780, 129–137.
CarnemollaSE, KumforF, LiangCT, FoxeD, AhmedRM, PiguetO (2022) Olfactory bulb integrity in frontotemporal dementia and Alzheimer’s Disease. J Alzheimers Dis89, 51–66.
24.
LeiY, ZhangJ, SchiavonCR, HeM, ChenL, ShenH, ZhangY, YinQ, ChoY, AndradeL (2021) SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res128, 1323–1326.
25.
DolatshahiM, SabahiM, AarabiMH (2021) Pathophysiological clues to how the emergent SARS-CoV-2 can potentially increase the susceptibility to neurodegeneration. Mol Neurobiol58, 2379–2394.
GarridoAM, GriendlingKK (2009) NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol302, 148–158.
28.
Nguyen Dinh CatA, MontezanoAC, BurgerD, TouyzRM (2013) Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal19, 1110–1120.
29.
CaradonnaA, PatelT, ToleskaM, AlabedS, ChangSL (2022) Meta-analysis of APP expression modulated by SARS-CoV-2 infection via the ACE2 receptor. Int J Mol Sci23, 1182.
HuN, TanM, YuJ, SunL, TanL, WangY, JiangT, TanL (2014) Increased expression of TREM2 in peripheral blood of Alzheimer’s disease patients. J Alzheimers Dis38, 497–501.
34.
WuY, WangM, YinH, MingS, LiX, JiangG, LiuY, WangP, ZhouG, LiuL (2021) TREM-2 is a sensor and activator of T cell response in SARS-CoV-2 infection. Sci Adv7, eabi6802.
35.
HollingworthP, HaroldD, SimsR, GerrishA, LambertJ, CarrasquilloMM, AbrahamR, HamshereML, PahwaJS, MoskvinaV (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet43, 429–435.
GuX, DouM, CaoB, JiangZ, ChenY (2022) Peripheral level of CD33 and Alzheimer’s disease: A bidirectional two-sample Mendelian randomization study. Transl Psychiatry12, 427.
38.
MurchSH (2020) Common determinants of severe Covid-19 infection are explicable by SARS-CoV-2 secreted glycoprotein interaction with the CD33-related Siglecs, Siglec-3 and Siglec-5/14. Med Hypotheses144, 110168.
39.
RahmanMA, IslamK, RahmanS, AlaminM (2021) Neurobiochemical cross-talk between COVID-19 and Alzheimer’s disease. Mol Neurobiol58, 1017–1023.
SiesH (1997) Oxidative stress: Oxidants and antioxidants. Exp Physiol82, 291–295.
49.
PoljšakB, FinkR (2014) The protective role of antioxidants in the defence against ROS/RNS-mediated environmental pollution. Oxid Med Cell Longev2014, 539–671.
50.
SchwarzKB (1996) Oxidative stress during viral infection: A review. Free Radic Biol Med21, 641–649.
51.
Delgado-RocheL, MestaF (2020) Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Arch Med Res51, 384–387.
52.
PincemailJ, CavalierE, CharlierC, Cheramy– BienJ, BreversE, CourtoisA, FadeurM, MezianeS, GoffCL, MissetB (2021) Oxidative stress status in COVID-19 patients hospitalized in intensive care unit for severe pneumonia. A pilot study. Antioxidants10, 257.
53.
AlamdariDH, MoghaddamAB, AminiS, KeramatiMR, ZarmehriAM, AlamdariAH, DamsazM, BanpourH, YarahmadiA, KoliakosG (2020) Application of methylene blue-vitamin C– N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol885, 173494.
FischerR, MaierO (2015) Interrelation of oxidative stress and inflammation in neurodegenerative disease: Role of TNF. Oxid Med Cell Longev2015, 610813.
56.
GiraldoE, LloretA, FuchsbergerT, ViñaJ (2014) Aβ and tau toxicities in Alzheimer’s are linked via oxidative stress-induced p38 activation: Protective role of vitamin E. Redox Biol2, 873–877.
57.
SultanaR, ButterfieldDA (2010) Role of oxidative stress in the progression of Alzheimer’s disease. J Alzheimers Dis19, 341–353.
58.
HardasSS, SultanaR, ClarkAM, BeckettTL, SzwedaLI, MurphyMP, ButterfieldDA (2013) Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biol1, 80–85.
59.
CuiH, KongY, ZhangH (2012) Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct2012, 646–354.
60.
OnyangoIG, KhanSM (2006) Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer’s disease. Curr Alzheimer Res3, 339–349.
61.
WangH, QinR, ZhangJ, ChenY (2021) Possible immunity, inflammation, and oxidative stress mechanisms of Alzheimer’s disease in COVID-19 patients. Clin Neurol Neurosurg201, 106414.
62.
ChiricostaL, GugliandoloA, MazzonE (2021) SARS-CoV-2 exacerbates beta-amyloid neurotoxicity, inflammation and oxidative stress in Alzheimer’s disease patients. Int J Mol Sci22, 13603.
63.
BirdTD (2008) Genetic aspects of Alzheimer disease. Genet Med10, 231–239.
64.
SeshadriS, FitzpatrickAL, IkramMA, DeStefanoAL, GudnasonV, BoadaM, BisJC, SmithAV, CarrasquilloMM, LambertJC (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA303, 1832–1840.
65.
StrittmatterWJ, RosesAD (1995) Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A92, 4725–4727.
66.
ChapuisJ, HansmannelF, GistelinckM, MounierA, Van CauwenbergheC, KolenKV, GellerF, SottejeauY, HaroldD, DourlenP (2013) Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry18, 1225–1234.
67.
SakamuroD, ElliottKJ, Wechsler-ReyaR, PrendergastGC (1996) BIN1 is a novel MYC– interacting protein with features of a tumour suppressor. Nat Genet14, 69–77.
68.
KuoC, PillingLC, AtkinsJL, MasoliJA, DelgadoJ, KuchelGA, MelzerD (2020) APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci75, 2231–2232.
LehrerS, RheinsteinPH (2021) BIN1 rs744373 SNP and COVID-19 mortality. World Acad Sci J3, 1.
71.
MagusaliN, GrahamAC, PiersTM, PanichnantakulP, YamanU, ShoaiM, ReynoldsRH, BotiaJA, BrookesKJ, Guetta-BaranesT (2021) A genetic link between risk for Alzheimer’s disease and severe COVID-19 outcomes via the OAS1 gene. Brain144, 3727–3741.
72.
AhmedSS, ParamasivamP, KamathM, SharmaA, RomeS, MurugesanR (2021) Genetic exchange of lung-derived exosome to brain causing neuronal changes on COVID-19 infection. Mol Neurobiol58, 5356–5368.
73.
KitamuraY, ShimohamaS, OtaT, MatsuokaY, NomuraY, TaniguchiT (1997) Alteration of transcription factors NF-κB and STAT1 in Alzheimer’s disease brains. Neurosci Lett237, 17–20.
74.
EvansIE, MartyrA, CollinsR, BrayneC, ClareL (2019) Social isolation and cognitive function in later life: A systematic review and meta-analysis. J Alzheimers Dis70, S119–S144.
75.
BennettDA, SchneiderJA, TangY, ArnoldSE, WilsonRS (2006) The effect of social networks on the relation between Alzheimer’s disease pathology and level of cognitive function in old people: A longitudinal cohort study. Lancet Neurol5, 406–412.
76.
BiddleKD, UquillasFd, JacobsHI, ZideB, KirnDR, RentzDM, JohnsonKA, SperlingRA, DonovanNJ (2019) Social engagement and amyloid-β-related cognitive decline in cognitively normal older adults. Am J Geriatr Psychiatry27, 1247–1256.
77.
WilsonRS, KruegerKR, ArnoldSE, SchneiderJA, KellyJF, BarnesLL, TangY, BennettDA (2007) Loneliness and risk of Alzheimer disease. Arch Gen Psychiatry64, 234–240.
78.
GongW, WangY, ZhouH, LiX, BaiF, RenQ, ZhangZ (2017) Citalopram ameliorates synaptic plasticity deficits in different cognition-associated brain regions induced by social isolation in middle-aged rats. Mol Neurobiol54, 1927–1938.
79.
Lavenda-GrosbergD, LalzarM, LeserN, YaseenA, MalikA, MarounM, Barki-HarringtonL, WagnerS (2022) Acute social isolation and regrouping cause short-and long-term molecular changes in the rat medial amygdala. Mol Psychiatry27, 886–895.
80.
PorcelliS, Van Der WeeN, van der WerffS, AghajaniM, GlennonJC, van HeukelumS, MogaveroF, LoboA, OliveraFJ, LoboE (2019) Social brain, social dysfunction and social withdrawal. Neurosci Biobehav Rev97, 10–33.
81.
MurínováJ, HlaváčováN, ChmelováM, RiečanskýI (2017) The evidence for altered BDNF expression in the brain of rats reared or housed in social isolation: A systematic review. Front Behav Neurosci11, 101.
82.
HsiaoY, ChenPS, ChenS, GeanP (2011) The involvement of Cdk5 activator p35 in social isolation-triggered onset of early Alzheimer’s disease-related cognitive deficit in the transgenic mice. Neuropsychopharmacology36, 1848–1858.
83.
KowiańskiP, LietzauG, CzubaE, WaśkowM, SteligaA, MoryśJ (2018) BDNF: A key factor with multipotent impact on brain signaling and synaptic plasticity. Cell Mol Neurobiol38, 579–593.
84.
BoscoA, LindenR (1999) BDNF and NT-4 differentially modulate neurite outgrowth in developing retinal ganglion cells. J Neurosci Res57, 759–769.
85.
BramhamCR, MessaoudiE (2005) BDNF function in adult synaptic plasticity: The synaptic consolidation hypothesis. Prog Neurobiol76, 99–125.
86.
ChaoMV (2003) Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci4, 299–309.
87.
GarzonDJ, FahnestockM (2007) Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci27, 2628–2635.
88.
PhillipsHS, HainsJM, ArmaniniM, LarameeGR, JohnsonSA, WinslowJW (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron7, 695–702.
89.
NgTKS, HoCSH, TamWWS, KuaEH, HoRC (2019) Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer’s disease (AD): A systematic review and meta-analysis. Int J Mol Sci20, 257.
DemirB, BeyazyüzE, BeyazyüzM, ÇelikkolA, AlbayrakY (2022) Long-lasting cognitive effects of COVID-19: Is there a role of BDNF?Eur Arch Psychiatry Clin Neurosci273, 1339–1347.
92.
AsgarzadehA, FouladiN, AsghariazarV, SarabiSF, KhiaviHA, MahmoudiM, SafarzadehE (2022) Serum brain-derived neurotrophic factor (BDNF) in COVID-19 patients and its association with the COVID-19 manifestations. J Mol Neurosci72, 1820–1830.
93.
Ruiz-GonzalezD, Hernandez-MartinezA, ValenzuelaPL, MoralesJS, Soriano-MaldonadoA (2021) Effects of physical exercise on plasma brain-derived neurotrophic factor in neurodegenerative disorders: A systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev128, 394–405.
94.
RibeiroD, PetrignaL, PereiraFC, MuscellaA, BiancoA, TavaresP (2021) The impact of physical exercise on the circulating levels of BDNF and NT 4/5: A review. Int J Mol Sci22, 8814.
95.
SavikangasT, TörmäkangasT, TirkkonenA, AlenM, FieldingRA, KivipeltoM, RantalainenT, Stigsdotter NeelyA, SipiläS (2021) The effects of a physical and cognitive training intervention vs. physical training alone on older adults’ physical activity: A randomized controlled trial with extended follow-up during COVID-19. PLoS One16, e0258559.
96.
WangQ, DavisPB, GurneyME, XuR (2021) COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement17, 1297–1306.
97.
ZhangQ, SchultzJL, AldridgeGM, SimmeringJE, KimY, OgilvieAC, NarayananNS (2021) COVID-19 case fatality and Alzheimer’s disease. J Alzheimers Dis84, 1447–1452.
98.
ZhouJ, LiuC, SunY, HuangW, YeK (2021) Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study. Brain Behav Immun91, 383–392.
99.
YuY, TravaglioM, PopovicR, LealNS, MartinsLM (2021) Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes: A UK Biobank study. Geriatrics6, 10.
100.
FathiM, TaghizadehF, MojtahediH, JameSZB, MoghaddamNM (2022) The effects of Alzheimer’s and Parkinson’s disease on 28-day mortality of COVID-19. Rev Neurol178, 129–136.
101.
ChungSJ, ChangY, JeonJ, ShinJI, SongT, KimJ (2022) Association of Alzheimer’s disease with COVID-19 susceptibility and severe complications: A nationwide cohort study. J Alzheimers Dis87, 701–710.
102.
O’ConnorRC, WetherallK, CleareS, McClellandH, MelsonAJ, NiedzwiedzCL, O’CarrollRE, O’ConnorDB, PlattS, ScowcroftE, WatsonB, ZorteaT, FergusonE, RobbKA (2021) Mental health and well-being during the COVID-19 pandemic: Longitudinal analyses of adults in the UK COVID-19 Mental Health & Wellbeing study. Br J Psychiatry218, 326–333.
